EP4289446A3 - Method and composition for treating ocular hypertension and glaucoma - Google Patents

Method and composition for treating ocular hypertension and glaucoma Download PDF

Info

Publication number
EP4289446A3
EP4289446A3 EP23202597.3A EP23202597A EP4289446A3 EP 4289446 A3 EP4289446 A3 EP 4289446A3 EP 23202597 A EP23202597 A EP 23202597A EP 4289446 A3 EP4289446 A3 EP 4289446A3
Authority
EP
European Patent Office
Prior art keywords
glaucoma
composition
ocular hypertension
treating ocular
ophthalmic solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23202597.3A
Other languages
German (de)
French (fr)
Other versions
EP4289446A2 (en
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4289446(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of EP4289446A2 publication Critical patent/EP4289446A2/en
Publication of EP4289446A3 publication Critical patent/EP4289446A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method for increasing aqueous solubility and improving stability of tafluprost in an aqueous ophthalmic solution, comprising the steps of preparing an aqueous ophthalmic solution containing 0.0010-0.0025% tafluprost, 0.075% polysorbate 80, 0.005-0.2% stabilizing agent and substantially no preservatives, and packaging the preservative-free ophthalmic solution in a container consisting essentially of polyethylene.
EP23202597.3A 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma Pending EP4289446A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP17000440.2A EP3205334B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP14001862.3A EP2772249B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP20164602.3A EP3714877B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP09754864.8A EP2306977B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP21217057.5A EP4035656B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Related Parent Applications (6)

Application Number Title Priority Date Filing Date
EP17000440.2A Division EP3205334B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP14001862.3A Division EP2772249B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP20164602.3A Division EP3714877B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP21217057.5A Division-Into EP4035656B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP21217057.5A Division EP4035656B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP09754864.8A Division EP2306977B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (2)

Publication Number Publication Date
EP4289446A2 EP4289446A2 (en) 2023-12-13
EP4289446A3 true EP4289446A3 (en) 2024-01-10

Family

ID=39940592

Family Applications (7)

Application Number Title Priority Date Filing Date
EP08397513A Withdrawn EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
EP14001862.3A Revoked EP2772249B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP17000440.2A Active EP3205334B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP21217057.5A Active EP4035656B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP20164602.3A Active EP3714877B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP09754864.8A Active EP2306977B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP23202597.3A Pending EP4289446A3 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Family Applications Before (6)

Application Number Title Priority Date Filing Date
EP08397513A Withdrawn EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
EP14001862.3A Revoked EP2772249B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP17000440.2A Active EP3205334B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP21217057.5A Active EP4035656B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP20164602.3A Active EP3714877B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP09754864.8A Active EP2306977B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Country Status (27)

Country Link
US (3) US9999593B2 (en)
EP (7) EP2127638A1 (en)
JP (9) JP2011521943A (en)
KR (5) KR101650006B1 (en)
CN (1) CN102083413B (en)
AR (2) AR071937A1 (en)
AU (1) AU2009252210C1 (en)
BR (1) BRPI0913109B8 (en)
CA (2) CA2724194C (en)
CY (2) CY1115565T1 (en)
DK (4) DK2306977T3 (en)
EA (1) EA023661B1 (en)
ES (5) ES2808050T3 (en)
GE (1) GEP20156220B (en)
HR (4) HRP20220361T1 (en)
HU (3) HUE033103T2 (en)
JO (1) JO3039B1 (en)
LT (3) LT2772249T (en)
MX (1) MX2010012987A (en)
MY (1) MY159463A (en)
PL (4) PL2772249T3 (en)
PT (4) PT3205334T (en)
SG (1) SG191628A1 (en)
SI (4) SI3714877T1 (en)
TW (1) TWI432202B (en)
UA (1) UA102257C2 (en)
WO (1) WO2009145356A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (en) 2008-03-17 2016-08-11 愛爾康研究有限公司 Pharmaceutical compositions having low concentration of surfactants for promoting bioavailability of therapeutic agents
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (en) * 2009-12-28 2015-03-11 ロート製薬株式会社 Ophthalmic composition
FR2961694B1 (en) * 2010-06-29 2013-01-25 Thea Lab POLYMERIC DELIVERY SYSTEM FOR NON-VISCOUS SOLUTION BASED ON PROSTAGLANDIN WITHOUT PRESERVATIVE
AU2011282681B2 (en) * 2010-07-29 2015-07-30 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP2598117A2 (en) * 2010-07-29 2013-06-05 Allergan, Inc. Preservative free bimatoprost solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2618810B1 (en) 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
CN102716074B (en) * 2012-06-28 2013-10-16 武汉武药科技有限公司 Bimatoprost eye drops and preparation method thereof
FI2887923T3 (en) * 2012-08-24 2023-06-30 Sun Pharmaceutical Ind Ltd Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (en) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 Method for preparing lithium ion battery cathode material by utilizing biomass gasification furnace filter residue
EP3103439B1 (en) 2015-06-09 2019-08-07 MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH Drippable ophthalmic bimatoprost gel
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
CA3004587A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
BR112018067946A8 (en) 2016-02-29 2022-11-08 Sun Pharma Global Fze TOPICAL FORMULATIONS CONTAINING CYCLOSPORINE AND USES THEREOF
GR1009040B (en) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Preservative free pharmaceutical ophthalmic compositions
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (en) * 2016-11-09 2017-08-22 주식회사태준제약 The ophthalmic composition for the ocular pressure drop
JP2020059652A (en) * 2016-12-26 2020-04-16 参天製薬株式会社 Depot formulation containing tafluprost and citric acid ester
ES2972844T3 (en) * 2017-03-27 2024-06-17 Alcon Inc Pharmaceutical preparation
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. Ophthalmic composition for glaucoma treatment
CN111479568A (en) * 2017-12-21 2020-07-31 参天制药株式会社 Combination of sppecprost and Rho kinase inhibitor
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
CN111632025A (en) * 2020-03-04 2020-09-08 吉林大学第一医院 Temperature-sensitive in-situ gel for bimatoprost eyes and preparation method and application thereof
CN111840225B (en) * 2020-08-12 2021-09-14 陈丽娜 Eye drop for treating glaucoma and preparation method thereof
RU2761625C2 (en) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Pharmaceutical composition of tafluprost
WO2023182480A1 (en) * 2022-03-25 2023-09-28 株式会社坪田ラボ Aqueous composition
WO2023241652A1 (en) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 Pharmaceutical composition, method for preparing same, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
EP1321144A1 (en) * 2000-09-13 2003-06-25 Santen Pharmaceutical Co., Ltd. Eye drops
EP1825855A1 (en) * 2004-12-09 2007-08-29 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin having fluorine atom in molecule

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (en) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid dispenser for aseptic fluid
JPH0655640A (en) 1992-08-04 1994-03-01 Aavan Internatl:Kk Sink counter and manufacture thereof
JPH06107547A (en) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk Composition for ophthalmolgy
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (en) 1993-01-20 1996-09-11 東洋製罐株式会社 Heat-sterilizable liquid medicine container
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU704938B2 (en) * 1995-11-17 1999-05-06 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
DE69714274T3 (en) 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. FLUORATED PROSTAGLANDINE DERIVATIVES AND MEDICAMENTS
WO1998025829A1 (en) 1996-12-09 1998-06-18 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (en) 1996-12-26 2003-12-22 参天製薬株式会社 Difluoroprostaglandin derivatives and uses thereof
AR002194A1 (en) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
EP0979652B1 (en) 1997-10-13 2006-05-24 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
JP2003517441A (en) 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド Sustained-release and comfortable composition for eye disease and method for treating eye disease
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2001264261A1 (en) 2000-06-19 2002-01-02 Santen Pharmaceutical Co. Ltd. Aseptics
JP3876355B2 (en) * 2000-09-13 2007-01-31 参天製薬株式会社 Ophthalmic solution
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
AU2003248070A1 (en) 2002-07-16 2004-02-02 Hanshin Yoki Co., Ltd. Chemical container and method of manufacturing the container
KR101253941B1 (en) 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 Transparent eye drops containing latanoprost
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1666043B1 (en) 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ATE412400T1 (en) 2004-11-09 2008-11-15 Novagali Pharma Sa OIL-IN-WATER EMULSION WITH LOW CATIONIC AGENT CONCENTRATION AND POSITIVE ZETA POTENTIAL
WO2007042262A2 (en) 2005-10-10 2007-04-19 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
WO2006058139A2 (en) 2004-11-24 2006-06-01 Holopack International Corp. Dispensing container with flow control system
DK1829545T3 (en) 2004-12-24 2012-07-23 Santen Pharmaceutical Co Ltd Products containing prostaglandin-F2alfa derivative
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2007007832A1 (en) 2005-07-13 2007-01-18 Santen Pharmaceutical Co., Ltd. Preservative composition for ophthalmic use
US8030349B2 (en) 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
FI126233B (en) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Vibrating grinder
FR2918891B1 (en) 2007-07-20 2009-09-25 Thea Sa Lab OPHTHALMIC SOLUTION BASED ON PROSTAGLANDINS WITHOUT PRESERVATIVE
KR100927617B1 (en) 2007-11-26 2009-11-23 한국표준과학연구원 Method of manufacturing a sensing part of a biosensor having nano size of pyrolysis carbon component
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
EP1321144A1 (en) * 2000-09-13 2003-06-25 Santen Pharmaceutical Co., Ltd. Eye drops
EP1825855A1 (en) * 2004-12-09 2007-08-29 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin having fluorine atom in molecule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRASNU E ET AL.: "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, vol. 33, no. 4, April 2008 (2008-04-01), pages 303 - 312, XP009108708 *
KUPPENS E V M ET AL.: "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, vol. 79, 1995, pages 339 - 342, XP009108698 *

Also Published As

Publication number Publication date
MY159463A (en) 2017-01-13
CA2724194C (en) 2017-06-27
PT3205334T (en) 2020-07-31
EP3714877A1 (en) 2020-09-30
US20210059931A1 (en) 2021-03-04
PL3714877T3 (en) 2022-05-16
JP2011521943A (en) 2011-07-28
EP4035656B1 (en) 2023-11-22
TW201000104A (en) 2010-01-01
US9999593B2 (en) 2018-06-19
US10864159B2 (en) 2020-12-15
ES2495316T3 (en) 2014-09-17
DK2772249T3 (en) 2017-07-17
CY1120351T1 (en) 2019-07-10
CA2965185A1 (en) 2009-12-03
KR101650006B1 (en) 2016-08-22
JP2018154656A (en) 2018-10-04
DK3205334T3 (en) 2020-07-13
EP2772249B1 (en) 2017-05-03
CN102083413A (en) 2011-06-01
SG191628A1 (en) 2013-07-31
US20110152264A1 (en) 2011-06-23
EP3205334B1 (en) 2020-04-29
KR20200057801A (en) 2020-05-26
HRP20200998T1 (en) 2020-10-16
HRP20140979T1 (en) 2014-11-21
EP2306977B1 (en) 2014-08-13
HUE033103T2 (en) 2017-11-28
JP6148317B2 (en) 2017-06-14
BRPI0913109B8 (en) 2021-05-25
EP2127638A1 (en) 2009-12-02
JP6889789B2 (en) 2021-06-18
HUE049923T2 (en) 2020-11-30
JP7265584B2 (en) 2023-04-26
JP2017178957A (en) 2017-10-05
SI3714877T1 (en) 2022-05-31
EP3205334A1 (en) 2017-08-16
LT3205334T (en) 2020-09-25
CA2724194A1 (en) 2009-12-03
JP2023085558A (en) 2023-06-20
EA201071413A1 (en) 2011-06-30
ES2627837T8 (en) 2018-02-26
AU2009252210A1 (en) 2009-12-03
JO3039B1 (en) 2016-09-05
WO2009145356A1 (en) 2009-12-03
EA023661B1 (en) 2016-06-30
EP2306977A1 (en) 2011-04-13
ES2907982T3 (en) 2022-04-27
HRP20220361T1 (en) 2022-05-13
CN102083413B (en) 2013-11-06
KR102114401B1 (en) 2020-05-25
JP7520285B2 (en) 2024-07-23
BRPI0913109A2 (en) 2017-06-20
KR102246598B1 (en) 2021-04-30
DK3714877T3 (en) 2022-02-14
AU2009252210C1 (en) 2016-04-14
PL3205334T3 (en) 2020-11-02
ES2968837T3 (en) 2024-05-14
KR101820816B1 (en) 2018-01-22
JP2016065095A (en) 2016-04-28
LT2772249T (en) 2017-09-11
KR20160102319A (en) 2016-08-29
AU2009252210B2 (en) 2014-10-16
TWI432202B (en) 2014-04-01
UA102257C2 (en) 2013-06-25
AR071937A1 (en) 2010-07-28
PT3714877T (en) 2022-03-10
SI2772249T1 (en) 2017-08-31
PL2306977T3 (en) 2015-01-30
BRPI0913109B1 (en) 2019-10-22
PT2772249T (en) 2017-08-08
JP6356868B2 (en) 2018-07-11
MX2010012987A (en) 2011-02-24
EP2772249A1 (en) 2014-09-03
EP3714877B1 (en) 2022-01-26
LT3714877T (en) 2022-04-11
HRP20170769T1 (en) 2017-08-11
DK2306977T3 (en) 2014-09-15
AR120961A2 (en) 2022-04-06
CY1115565T1 (en) 2017-01-04
JP2020073574A (en) 2020-05-14
SI2306977T1 (en) 2014-12-31
SI3205334T1 (en) 2020-10-30
PL2772249T3 (en) 2017-10-31
HUE058079T2 (en) 2022-06-28
US20180289618A1 (en) 2018-10-11
ES2808050T3 (en) 2021-02-25
JP2021120412A (en) 2021-08-19
KR20180008905A (en) 2018-01-24
ES2627837T3 (en) 2017-07-31
JP2024079852A (en) 2024-06-11
JP2014133765A (en) 2014-07-24
EP4035656A1 (en) 2022-08-03
KR101988642B1 (en) 2019-06-12
JP6649992B2 (en) 2020-02-19
KR20190067272A (en) 2019-06-14
GEP20156220B (en) 2015-01-26
PT2306977E (en) 2014-09-22
EP4289446A2 (en) 2023-12-13
KR20110011707A (en) 2011-02-08

Similar Documents

Publication Publication Date Title
EP4289446A3 (en) Method and composition for treating ocular hypertension and glaucoma
KR100849537B1 (en) Nano-emulsion composition of coenzyme q10
WO2006101839A3 (en) Enhanced bimatoprost ophthalmic solution
JP2016065095A5 (en)
JP2022116357A (en) Ophthalmic compositions comprising levodopa, antioxidant and aqueous carrier
MX2012012846A (en) Ophthalmic composition.
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
CA2717605A1 (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
KR20110005801A (en) Pharmaceutical compositions having desirable bioavailability
WO2009120549A3 (en) Methods to increase permeability of corneal epithelium and destabilize stromal collagen fibril network
US20140088107A1 (en) Ophthalmic preparation comprising a pgf2alpha analogue
WO2010141586A3 (en) Therapeutic ophthalmic emulsions
JP2018104479A (en) Aqueous ophthalmic composition
WO2007112130A3 (en) Automatic epithelial delaminator and lens inserter
JP5953358B2 (en) Ophthalmic composition for silicone hydrogel contact lens
IL256071A (en) Drippable ophthalmic bimatoprost gel
BR112012017319A2 (en) compositions and methods for lowering intraocular pressure
JP6177594B2 (en) Aqueous ophthalmic composition
JP2011063624A5 (en)
RU2018119685A (en) LIQUID BEVERAGE CONCENTRATE WITH SOLUBLE FIBERS AND METHOD OF DELIVERY OF SOLUBLE FIBER
JP2012056875A (en) Soft contact lens ophthalmic composition
EP2632427A1 (en) Ophthalmic composition
WO2010046865A3 (en) Ophthalmic administration of a composition including brimonidine as a mist
JP2013256475A (en) Ophthalmic aqueous composition containing glycyrrhizic acid
RU2017142726A (en) Ophthalmic composition containing lipoic acid and mucomimetic polymer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047180000

Ipc: A61K0009080000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 2306977

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2772249

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3205334

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3714877

Country of ref document: EP

Kind code of ref document: P

Ref document number: 4035656

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/18 20170101ALI20231201BHEP

Ipc: A61K 47/26 20060101ALI20231201BHEP

Ipc: A61K 47/10 20170101ALI20231201BHEP

Ipc: A61K 31/5575 20060101ALI20231201BHEP

Ipc: A61K 9/08 20060101AFI20231201BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE